| Primary |
| Drug Use For Unknown Indication |
17.6% |
| Depression |
15.3% |
| Product Used For Unknown Indication |
14.1% |
| Schizophrenia |
11.8% |
| Bipolar Disorder |
8.2% |
| Overdose |
7.1% |
| Psychotic Disorder |
3.5% |
| Tuberculosis |
3.5% |
| Anxiety |
2.4% |
| Pain |
2.4% |
| Schizophrenia, Disorganised Type |
2.4% |
| Schizophrenia, Paranoid Type |
2.4% |
| Adjustment Disorder |
1.2% |
| Autism |
1.2% |
| Convulsion |
1.2% |
| Drug Withdrawal Syndrome Neonatal |
1.2% |
| Dyspepsia |
1.2% |
| Hiccups |
1.2% |
| Hypertension |
1.2% |
| Insomnia |
1.2% |
|
| Liver Injury |
18.4% |
| Death |
13.2% |
| Electrocardiogram Qt Prolonged |
7.9% |
| Neuroleptic Malignant Syndrome |
7.9% |
| Lethargy |
5.3% |
| Overdose |
5.3% |
| Serotonin Syndrome |
5.3% |
| White Blood Cell Count Decreased |
5.3% |
| Cellulitis |
2.6% |
| Central Nervous System Inflammation |
2.6% |
| Conjunctivitis |
2.6% |
| Convulsion |
2.6% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.6% |
| Hepatocellular Damage |
2.6% |
| Intestinal Infarction |
2.6% |
| Intestinal Obstruction |
2.6% |
| Kidney Malformation |
2.6% |
| Liver Disorder |
2.6% |
| Microcephaly |
2.6% |
| Miosis |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
30.0% |
| Schizophrenia |
16.7% |
| Insomnia |
6.5% |
| Depression |
5.1% |
| Drug Use For Unknown Indication |
4.1% |
| Parkinsonism |
4.0% |
| Foetal Exposure During Pregnancy |
3.8% |
| Psychotic Disorder |
3.6% |
| Bipolar Disorder |
3.3% |
| Anxiety |
3.2% |
| Major Depression |
2.5% |
| Multiple Sclerosis |
2.5% |
| Self Injurious Behaviour |
2.5% |
| Dissociative Disorder |
2.3% |
| Delusion |
1.7% |
| Maternal Exposure Timing Unspecified |
1.7% |
| Oedema |
1.7% |
| Suicide Attempt |
1.7% |
| Vomiting |
1.7% |
| Binge Drinking |
1.5% |
|
| Neuroleptic Malignant Syndrome |
11.0% |
| Completed Suicide |
8.2% |
| Multiple Drug Overdose |
8.2% |
| Torsade De Pointes |
8.2% |
| Cholestasis |
5.5% |
| Suicide Attempt |
5.5% |
| Toxicity To Various Agents |
5.5% |
| Ventricular Tachycardia |
5.5% |
| White Blood Cell Count Decreased |
5.5% |
| Aggression |
4.1% |
| Catatonia |
4.1% |
| Death |
4.1% |
| Muscle Rigidity |
4.1% |
| Rhabdomyolysis |
4.1% |
| Abdominal Compartment Syndrome |
2.7% |
| Abdominal Pain |
2.7% |
| Alanine Aminotransferase Increased |
2.7% |
| Cardio-respiratory Arrest |
2.7% |
| Drug Effect Decreased |
2.7% |
| Drug Exposure During Pregnancy |
2.7% |
|
| Concomitant |
| Schizophrenia |
24.0% |
| Product Used For Unknown Indication |
22.8% |
| Depression |
6.9% |
| Drug Use For Unknown Indication |
5.8% |
| Prophylaxis |
5.7% |
| Pain |
4.3% |
| Insomnia |
3.9% |
| Multiple Myeloma |
3.6% |
| Anxiety |
2.6% |
| Hypertension |
2.3% |
| Psychotic Disorder |
2.3% |
| Epilepsy |
2.1% |
| Hiv Infection |
2.0% |
| Infection Prophylaxis |
1.9% |
| Bipolar Disorder |
1.8% |
| Bipolar I Disorder |
1.7% |
| Dissociative Disorder |
1.7% |
| Schizophrenia, Paranoid Type |
1.7% |
| Premedication |
1.5% |
| Psychiatric Symptom |
1.4% |
|
| Water Intoxication |
10.1% |
| Vomiting |
7.3% |
| Weight Decreased |
6.4% |
| White Blood Cell Count Decreased |
6.4% |
| Hyperglycaemia |
5.5% |
| Jaundice |
5.5% |
| White Blood Cell Count Increased |
5.5% |
| Death |
4.6% |
| Loss Of Consciousness |
4.6% |
| Neuroleptic Malignant Syndrome |
4.6% |
| Overdose |
4.6% |
| Pulmonary Embolism |
4.6% |
| Ventricular Tachycardia |
4.6% |
| Hepatic Function Abnormal |
3.7% |
| Muscle Hypertrophy |
3.7% |
| Off Label Use |
3.7% |
| Red Blood Cell Count Decreased |
3.7% |
| Renal Failure |
3.7% |
| Schizophrenia |
3.7% |
| Tremor |
3.7% |
|
| Interacting |
| Product Used For Unknown Indication |
59.1% |
| Drug Use For Unknown Indication |
13.6% |
| Schizophrenia |
13.6% |
| Parkinson's Disease |
6.8% |
| Bipolar I Disorder |
4.5% |
| Hypercholesterolaemia |
2.3% |
|
| Drug Interaction |
50.0% |
| Rhabdomyolysis |
25.0% |
| Urinary Retention |
25.0% |
|
